Literature DB >> 32463748

Changing practice: moving to a specialist nurse-led service for BRCA gene testing.

Nicola Scott1, Jackie O'Sullivan1, Kristjan Asgeirsson2, Douglas Macmillan2, Emma Wilson3.   

Abstract

Some 5-10% of all breast cancers are associated with a pathogenic variant in a breast cancer-associated gene (BRCA1/BRCA2). Historically, with referral to the Nottingham University Hospitals NHS Trust's clinical genetics department for genetic testing, waiting times were on average 12-14 weeks for an initial appointment and 4-6 months to obtain results from the date of testing. A specialist, nurse-led mainstreaming cancer genetics (MCG) service was set up in the trust's Nottingham Breast Institute (NBI) to: reduce waiting times for the initial consultation, counselling, consent and obtaining results for BRCA1/BRCA2 gene testing; and to ensure appropriate patients with breast cancer were offered genetic testing. Two breast clinical nurse specialists were trained so they could counsel, consent and give results for the BRCA1/BRCA2 gene testing directly to patients. Average waiting times for results from the time of testing were reduced to 35.8 days under the nurse-led service, which enabled oncologists and patients to consider individual treatment options at an earlier time. The MCG service reduced waiting times, resulting in an improved, more streamlined service for patients undergoing genetic testing. The MCG service extended the scope of practice of the breast nurse clinical specialists, embedded an expert advanced nursing role in the breast multidisciplinary team and developed nurse mentoring opportunities.

Entities:  

Keywords:  BRCA; Breast cancer; Mainstreaming cancer genetics; Nurse-led clinical genetics; Triple negative cancer

Mesh:

Year:  2020        PMID: 32463748     DOI: 10.12968/bjon.2020.29.10.S6

Source DB:  PubMed          Journal:  Br J Nurs        ISSN: 0966-0461


  3 in total

1.  A pilot study investigating feasibility of mainstreaming germline BRCA1 and BRCA2 testing in high-risk patients with breast and/or ovarian cancer in three tertiary Cancer Centres in Ireland.

Authors:  Terri Patricia McVeigh; Karl J Sweeney; Donal J Brennan; Una M McVeigh; Simon Ward; Ann Strydom; Sheila Seal; Katherine Astbury; Paul Donnellan; Joanne Higgins; Maccon Keane; Michael J Kerin; Carmel Malone; Pauline McGough; Ray McLaughlin; Michael O'Leary; Margaret Rushe; Michael Kevin Barry; Geraldine MacGregor; Michael Sugrue; Ala Yousif; Dhafir Al-Azawi; Eileen Berkeley; Terence J Boyle; Elizabeth M Connolly; Carmel Nolan; Elaine Richardson; Claire Giffney; Samantha B Doyle; Sheila Broderick; William Boyd; Ruaidhri McVey; Thomas Walsh; Michael Farrell; David J Gallagher; Nazneen Rahman; Angela J George
Journal:  Fam Cancer       Date:  2022-08-27       Impact factor: 2.446

Review 2.  The Feasibility of Implementing Mainstream Germline Genetic Testing in Routine Cancer Care-A Systematic Review.

Authors:  Kyra Bokkers; Michiel Vlaming; Ellen G Engelhardt; Ronald P Zweemer; Inge M van Oort; Lambertus A L M Kiemeney; Eveline M A Bleiker; Margreet G E M Ausems
Journal:  Cancers (Basel)       Date:  2022-02-19       Impact factor: 6.639

3.  Timely Genetic Testing and Therapy Management in Patients With gBRCA-Mutated Metastatic Breast Cancer Receiving Talazoparib.

Authors:  Ashley Martinez; Tiffany Jones; Joanne C Ryan; Chad M Barnett; Elpitha L Soussou; Sarah Donahue
Journal:  J Adv Pract Oncol       Date:  2022-10-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.